Abstract:The coronavirus SARS-CoV-2 caused the COVID-19 global pandemic leading to 5.3 million deaths worldwide as of December 2021. The human intestine was found to be a major viral target which could have a strong impact on virus spread and pathogenesis since it is one of the largest organs. While type I interferons (IFNs) are key cytokines acting against systemic virus spread, in the human intestine type III IFNs play a major role by restricting virus infection and dissemination without disturbing homeostasis. Recent studies showed that both type I and III IFNs can inhibit SARS-CoV-2 infection, but it is not clear whether one IFN controls SARS-CoV-2 infection of the human intestine better or with a faster kinetics. In this study, we could show that type I and III IFNs both possess antiviral activity against SARS-CoV-2 in human intestinal epithelial cells (hIECs); however, type III IFN is more potent. Shorter type III IFN pretreatment times and lower concentrations were required to efficiently reduce virus load compared to type I IFNs. Moreover, type III IFNs significantly inhibited SARS-CoV-2 even 4 h postinfection and induced a long-lasting antiviral effect in hIECs. Importantly, the sensitivity of SARS-CoV-2 to type III IFNs was virus specific since type III IFN did not control VSV infection as efficiently. Together, these results suggest that type III IFNs have a higher potential for IFN-based treatment of SARS-CoV-2 intestinal infection compared to type I IFNs. IMPORTANCE SARS-CoV-2 infection is not restricted to the respiratory tract and a large number of COVID-19 patients experience gastrointestinal distress. Interferons are key molecules produced by the cell to combat virus infection. Here, we evaluated how two types of interferons (type I and III) can combat SARS-CoV-2 infection of human gut cells. We found that type III interferons were crucial to control SARS-CoV-2 infection when added both before and after infection. Importantly, type III interferons were also able to produce a long-lasting effect, as cells were protected from SARS-CoV-2 infection up to 72 h posttreatment. This study suggested an alternative treatment possibility for SARS-CoV-2 infection.

Interferon-lambda: New role in intestinal symptoms of COVID-19

Increased Sensitivity of SARS-CoV-2 to Type III Interferon in Human Intestinal Epithelial Cells

A Commentary of “type I Interferon Deficiency Can Lead to Severe COVID-19” in 10 Remarkable Discoveries from 2020 in Nature

Interferon lambda in respiratory viral infection: immunomodulatory functions and antiviral effects in epithelium

Specialized interferon action in COVID-19

IFN Lambda Deficiency Contributes to Severe COVID-19 Outcomes

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

COVID-19 and gut immunomodulation

Interferon-I modulation and natural products: Unraveling mechanisms and therapeutic potential in severe COVID-19

Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms

Intestinal Receptor of SARS-CoV-2 in Inflamed IBD Tissue Seems Downregulated by HNF4A in Ileum and Upregulated by Interferon Regulating Factors in Colon

COVID-19 and inflammatory bowel disease crosstalk: From emerging association to clinical proposal

Pathogenesis and Mechanism of Gastrointestinal Infection With COVID-19

Role of interferons in the antiviral battle: from virus-host crosstalk to prophylactic and therapeutic potential in SARS-CoV-2 infection

Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic Options

SARS-CoV-2 infection threatening intestinal health: A review of potential mechanisms and treatment strategies

FMT: A Potential Therapeutic and Rehabilitative Intervention for COVID-19

The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications

BACTERIAL TRANSLOCATION: MICROBIOTA-INTESTINE-LUNG AXIS AND PRO-INFLAMMATORY STATUS IN THE SEVERITY OF COVID-19

The mechanism and treatment of gastrointestinal symptoms in patients with COVID-19

Involvement of digestive system in COVID-19: manifestations, pathology, management and challenges